TEVA-TOPISONE 0.05 %
BETAMETHASONE (BETAMETHASONE DIPROPIONATE) : 0.05 % · DIN 00809187 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-TOPISONE?
TEVA-TOPISONE 0.05 % contains BETAMETHASONE (BETAMETHASONE DIPROPIONATE) : 0.05 %. It is listed in the Health Canada Drug Product Database under DIN 00809187, held by TEVA CANADA LIMITED, supplied as LOTION for TOPICAL administration. Health Canada currently lists it as marketed, status dated 20-Sep-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-TOPISONE used for?
Topical management of corticosteroid-responsive dermatoses, including psoriasis, contact dermatitis, atopic dermatitis, neurodermatitis, seborrheic dermatitis, and pruritus.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00809187 |
|---|---|
| Brand name | TEVA-TOPISONE |
| Generic / active ingredient | BETAMETHASONE (BETAMETHASONE DIPROPIONATE) : 0.05 % |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 0.05 % |
| Dosage form | LOTION |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D07AC01 BETAMETHASONE |
| AHFS class | 84:06.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Sep-2017 |
| Original market date | 1990-12-31 00:00:00 |
How is it administered?
Apply a thin film to cover the affected area and massage gently into the skin, usually twice daily.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C and 30°C.
How is it supplied?
Cream/Ointment: Tubes of 15 g and 50 g. Lotion: Plastic bottles of 30 mL and 75 mL.
Contraindications
Hypersensitivity to the drug or ingredients; untreated bacterial, tubercular, and fungal skin infections; certain viral diseases (herpes simplex, chicken pox, vaccinia).
Warnings and precautions
Not for ophthalmic use. Systemic absorption may occur over large areas or with occlusive dressings. May cause HPA axis suppression. Visual disturbances (cataract, glaucoma) reported.
What can be used instead?
Other Canadian products sharing ATC code D07AC01 BETAMETHASONE. 20 of 73 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BETADERM CRM 0.05% | 0.05 % | CREAM | TARO PHARMACEUTICALS INC | MARKETED | DIN 00716618 |
| BETADERM CRM 0.1% | 0.1 % | CREAM | TARO PHARMACEUTICALS INC | MARKETED | DIN 00716626 |
| BETADERM LOTION 0.1% | 0.1 % | LOTION | TARO PHARMACEUTICALS INC | MARKETED | DIN 00716634 |
| BETADERM ONT 0.05% | 0.05 % | OINTMENT | TARO PHARMACEUTICALS INC | MARKETED | DIN 00716642 |
| BETADERM ONT 0.1% | 0.1 % | OINTMENT | TARO PHARMACEUTICALS INC | MARKETED | DIN 00716650 |
| DIPROLENE | 0.05 % | OINTMENT | ORGANON CANADA INC. | MARKETED | DIN 00629367 |
| DIPROSONE | 0.05 % | LOTION | ORGANON CANADA INC. | MARKETED | DIN 00417246 |
| DIPROSONE | 0.05 % | CREAM | ORGANON CANADA INC. | MARKETED | DIN 00323071 |
| DIPROSONE | 0.05 % | OINTMENT | ORGANON CANADA INC. | MARKETED | DIN 00344923 |
| TARO-SONE | 0.05 % | CREAM | TARO PHARMACEUTICALS INC | MARKETED | DIN 01925350 |
Who else supplies BETAMETHASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BETAMETHASONE appears in 2437 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.